BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and n-Lorem Foundation, a nonprofit organization, today announced a strategic collaboration and global exclusive license agreement to develop a ...
Business Wire

Second Anniversary for n-Lorem Foundation Marks Extraordinary Progress Toward Treating Nano-Rare Patients

SAN DIEGO, Calif.--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, celebrates two years of progress in pioneering a novel non-profit approach to providing personalized experimental antisense ...
Business Wire

n-Lorem Foundation Initiates Clinical Trials for Three Nano-rare Patients

To date, n-Lorem has assisted in the development and treatment of 14 nano-rare patients and received over 160 applications for treatment with more than 80 nano-rare patients approved. n-Lorem was ...
Yahoo Finance

Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders

As part of the agreement, n-Lorem research teams will leverage their pioneering ASO technology platform to engineer preclinical candidates, which Servier will advance into clinical development.
Nasdaq

n-Lorem Foundation Partners with Ultragenyx to Bolster Development of Personalized Medicines for Patients with Ultra-Rare Diseases

Foundation’s collaboration with premier rare disease company strengthens efforts to reach more patients in need n-Lorem Foundation is the first and only foundation with a mission to provide ...
Morningstar

n-Lorem Foundation Announces the 50th Nano-rare Patient Receives Personalized ASO Medicine

No ASO-related serious adverse events and an excellent overall safety and tolerability record One patient treated for more than three years and 24 patients treated for >1 year n-Lorem, a nonprofit ...
AdnKronos

n-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic Diseases

SAN DIEGO and GENEVA, Jan. 13, 2026 /PRNewswire/ -- The n-Lorem Foundation and the EspeRare Foundation announced today a strategic collaboration to expand access in Europe to n-Lorem's antisense ...
GEN

n-Lorem Makes Ultrarare Disease Treatment Personal

Retirement typically means more time for traveling, hobbies, and relaxation. For Stan Crooke, MD, PhD, it means something very different. Crooke, the founder and executive chairman of Ionis ...
PharmiWeb

n-Lorem Foundation Organizes Third Annual Nano-rare Patient Colloquium, Highlighting Scientific and Clinical Advancements Achieved Since Organization’s Founding

Hosted by Biogen, the Colloquium brings together leading investigators and physicians with patients, partners and supporters to discuss progress in addressing nano-rare illnesses n-Lorem has ...
Yahoo Finance

Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders

SURESNES, France and SAN DIEGO, June 10, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical company governed by a foundation, and n-Lorem Foundation, a non-profit organization ...
Morningstar

Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders

Partnership will combine n-Lorem's cutting-edge antisense oligonucleotide (ASO) technology and Servier's R&D expertise with the aim of advancing ASO technology and delivering precision medicine ...